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Abstract
Background
Accurate classification of patients with inflammatory bowel disease into the subtypes ulcera-
tive colitis (UC) and Crohn’s disease (CD) is still a challenge, but important for therapy and
prognosis.
Objectives
To evaluate the diagnostic utility of anti-neutrophil cytoplasmic antibodies specific for pro-
teinase-3 (PR3-ANCA) for ulcerative colitis (UC) and the value of an antibody panel incorpo-
rating PR3-ANCA to differentiate between Crohn’s disease (CD) and UC.
Study design
In this cohort study, 122 pediatric and adolescent individuals were retrospectively included
(61 IBD patients of two clinical centers, 61 non-IBD controls). All subjects had a comprehen-
sive antibody profile done from stored sera taken close to time of diagnosis. By employing
quasi-exhaustive logistic regression the best discriminative model for UC and CD,subjects
was determined in a training cohort and confirmed in a validation cohort.
Results
PR3-ANCA was specifically associated with UC (odds ratio (OR), 17.6; 95% confidence
interval (CI); 3.6, 87); P < .001). A four antibody-panel including PR3-ANCA had an AUC of
90.81% (95%CI; 81.93, 99.69) to distinguish between UC and CD in the training cohort. In a
smaller external validation cohort, the AUC was 84.13% (95%CI; 64.21, 100) for accurate
diagnosis of CD and UC.
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Conclusion
PR3-ANCA is highly specific for UC. The differentiating capability of a panel, which contains
PR3-ANCA and weighs broadly available antibodies, is superior and utilization of the panel
can support accurate classification in the work-up of pediatric and adolescent patients with
IBD patients.
Introduction
Inflammatory bowel disease (IBD) is a generic term for chronic relapsing inflammatory dis-
eases of the intestine. The main subtypes are Crohn’s disease (CD) and ulcerative colitis (UC).
Accurate classification into the subtypes is important for appropriate management. However
establishing the correct diagnosis is sometimes challenging due to atypical presentations [1].
Despite a broad work-up based on a combination of history, physical and laboratory examina-
tion, esophagogastroduodenoscopy and ileocolonoscopy with histologyas well as imaging of
the small bowel in a substantial number of patients a classification is not possible [2] or
patients need to be reclassified during the course of the disease [3,4].
The revised Porto criteria for the diagnosis of IBD in children and adolescents discusses the
value of antibody testing for diagnosing IBD and concludes that performing antibody testing
may help to distinguish between CD and UC [5]. However, the limitation that fewer serologi-
cal markers are specifically associated with UC than with CD is acknowledged. An important
advantage of antibody determination in contrast to other biomarkers such as acute phase pro-
teins, is their relatively stationary prevalence over time regardless of treatment [6–8].
There are two main diagnostic tools for antibody detection, indirect immunofluorescence
(IIF), where staining patterns on different tissues and cells can be examined, and chemilumi-
nescent immunoassay (CLIA) as well as enzyme-linked immunosorbent assay (ELISA), which
allow a quantitative analysis of antibodies against specific antigens.
Anti-Saccharomyces cerevisiae antibodies (ASCA) and anti-neutrophil cytoplasmic antibod-
ies (ANCA) are the most investigated antibodies in IBD. Due to their staining patterns in IIF
ANCA can be divided into pANCA with perinuclear, cANCA with cytoplasmic, and xANCA
(also called “atypical ANCA”) with a rim-like perinuclear fluorescence (S1 Fig.) [9]. In ANCA-
associated vasculitis, pANCA, mainly directed against myeloperoxidase (MPO-ANCA), is a
well-established and very specific marker for microscopic polyangiitis, whereas proteinase 3
(PR3)-ANCA is the “classical” cANCA antigen and specific for granulomatosis with polyangii-
tis also known as Wegener’s granulomatosis [10]. Recently, PR3-ANCA not implicit in addi-
tion to the “classical” IIF cANCA staining pattern, was shown to be associated with UC in
adults [11,12]. PR3-ANCA positivity not only had a comparable sensitivity but also a favorable
specificity for UC than classical antibodies or their combinations [11]. Also a prognostic value
was suggested as PR3-ANCA reactivity was associated with a more extensive disease location
[12].
Other antibodies previously examined for their specificity for a subtype of IBD are exocrine
pancreatic autoantibodies (PAB) against glycoproteins of the pancreatic acini for CD [13] and
autoantibodies against goblet cells (GAB) for UC [14,15]. Determination of both antibodies
may be explicitly important in children and adolescents as PAB antibodies seem to be more
prevalent in CD patients diagnosed before the age of 17 years [13]. Reactivity of GAB on gas-
tric tissue (gGAB), suggests that this reactivity is not with goblet cells per se, but with compo-
nents of mucous which can also be found in gastric mucous producing cells [16]. This fact
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may prime those antibodies to be characteristic of childhood-onset IBD with its higher preva-
lence of upper gastrointestinal tract disease in comparison to adults [17].
The aim of our study was to investigate the value of PR3-ANCA determination for diagnos-
ing UC in a pediatric and adolescent cohort of IBD patients. Furthermore, we performed an
extensive antibody profiling of our cohort to gain an optimal antibody panel to differentiate
between CD and UC by employing quasi-exhaustive logistic regression modeling. Therefore,
the prevalence of ASCA IgA and IgG, pANCA, cANCA, xANCA, PR3-ANCA, MPO-ANCA,
PAB, and gGAB was determined. In a secondary analysis, the capability of antibodies to pre-
dict disease phenotype and behavior was assessed.
Materials and methods
Study population and design
A total of 61 pediatric and adolescent IBD patients up to the age of 18 years from two centers,
the University Children’s Hospital Bern and the Children’s Hospital Lucerne and 61 non-IBD
patients were enrolled retrospectively. All UC and CD patients were diagnosed according to
the Porto criteria [5,18] and their clinical data was collected by chart review. Clinical data
included age at diagnosis and serum sampling, gender, anthropometric measurements, disease
specific activity scores (pediatric ulcerative colitis activity index (PUCAI) and weighted pediat-
ric Crohn’s disease activity index (wPCDAI) for UC and CD, respectively), laboratory results
at diagnosis and serum sampling, extra-intestinal manifestations (erythema nodosum, arthri-
tis, hepatopathies including primary sclerosing cholangitis and autoimmune hepatitis, uveitis),
complications (stricturing or penetrating disease), medical treatment, and need for surgery
during follow-up. Disease location at time of diagnosis and disease behavior over time were
classified according to the Paris Classification. Age- and sex- matched non-IBD patients were
enrolled from our gastroenterology clinics with symptoms resembling IBD such as abdominal
pain, diarrhea, rectal bleeding, and weight loss and subsequently diagnosed with functional
gastrointestinal disorders according to standard diagnostic criteria [19]. All non-IBD patients
had negative serological celiac disease screening. For these patients age and sex at serum sam-
pling were documented. Auto- and antimicrobial antibodies were determined in stored serum
samples collected between December 2009 and April 2014. The study was approved by the
Ethics Committee of Canton Bern, Switzerland (Ref.-Nr. KEK-BE 018/14) and conducted in
accordance with the Helsinki declaration. The ethics committee waived the requirement for
written informed consent.
Analysis of antibodies
All sera were analyzed in a blinded fashion without knowledge of patient diagnosis or other
clinical information. For determination of ANCA, sera were incubated on Ethanol-fixed neu-
trophil granulocytes (INOVA Dx, San Diego). Positive patterns were further divided into cyto-
plasmic (cANCA), perinuclear (pANCA) or rim-like atypical (xANCA) staining (S1 Fig.). All
sera were additionally analyzed for PR3-ANCA and MPO-ANCA using commercial kits based
on CLIA Bioflash technology (INOVA Dx, San Diego). ASCA IgA and IgG were determined
using commercial ELISA kits (INOVA Dx, San Diego). Antibodies against exocrine pancreas
(PAB) antigens rPAg1 (CUZD1) and rPAg2 (GP2) as well as GAB were determined using IIF
on cells transfected with the specific antigen (Euroimmun, Lu¨beck, Germany). gGAB were
detected on commercially available murine triple-substrate tissue slides (kidney, stomach,
liver; Immco Dx, New York, USA) (S2 Fig.). All tests were performed according to the manu-
facturer’s instructions and were carried out in the routine diagnostic laboratory. Normal refer-
ence values as used in routine diagnostic were applied: xANCA, cANCA, pANCA, and gGAB
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<1:80 titer; PAB and GAB <1:10 titer; ASCA IgA and IgG <20U/ml; PR3-ANCA <5.0U/ml;
MPO-ANCA <6.0U/ml.
Statistical analysis
Univariate analysis was performed using Wilcoxon rank score test for continuous variables,
and Chi square or Fisher’s exact test for categorical variables. Sensitivity, specificity, positive
and negative predictive value (PPV, NPV) were calculated for each antibody alone or in com-
bination with other antibodies in order to predict the disease subtype.
Based on the Akaike Information Criterion (AIC), an efficient branch-and-bound algo-
rithm for a quasi- exhaustive search for the best subsets of the variables was used [20]. The
dichotomous diagnosis class (UC vs CD) was used as dependent and the antibodies as inde-
pendent variables (R v.3.3.3, package ‘gputools_1.1’) and the model space was assessed using
‘leaps’-based (package ‘leaps_3.0’) wrapper functions. ROC curves were drawn with the pROC
package (v. 1.9.1), the computation of optimal cutoffs was done with Youden’s J statistic (pack-
age pROC). For power calculations, the power.roc.test() function of the pROC package for R,
based on Obuchowski et al was used. [21]. Power calculation revealed that for the training
cohort (18 CD and 26 UC patients) the power was 99% using a two-tailed test with alpha set at
the conventional level of .05 for the reached AUC of 90.81%. The required sample size for a
power of 80% would have been 18 patients. All analyses were performed using SAS software,
version 9.3 (SAS Institute, Cary, NC) or R, version 3.3.3 (The R Foundation, Vienna). A p-
value <0.05 was considered statistically significant for all analyses.
Results
Clinical characteristics
Table 1 shows the clinical characteristics of the study population. Median time lapse between
diagnosis of IBD and serum sampling was 4.3 months [interquartile range (IQR): 0, 57.6]. At time
of serum sampling most patients had already received treatment at the discretion of the treating
physician and activity scores had improved (wPCDAI for CD patients, median [IQR]: 48 [35, 93]
at diagnosis vs. 25 [0, 93] at serum sampling; PUCAI for UC patients, median [IQR]: 45 [33, 85]
Table 1. Clinical characteristics of study population.
clinical characteristic IBD CD UC non-IBD
number of patients 61 28 33 61
males, n (%) 32 (52) 17 (61) 15 (45) 28 (46)
age at diagnosis, median [interquartile range (IQR)], y 11.2 [7.5,12.9] 10.8 [7.4,12.7] 11.3 [8.6,13.4] -
age at serum sampling, median [IQR], y 13.4 [10.9,15.7] 13.1 [10.8,15.7] 13.8 [11.2,15.7] 12.4 [9.3,14.1]
disease location at diagnosis in CD, n (%)
L1: ileal 5 (18)
L2: colonic 8 (29)
L3: ileocolonic 15 (54)
L4a: upper disease proximal 13 (46)
L4b: upper disease distal 3 (11)
disease location at diagnosis in UC, n (%)
E1: ulcerative proctitis 0
E2: left-sided UC (distal to splenic flexure) 6 (18)
E3: extensive (distal to hepatic flexure) 5 (15)
E4: pancolitis (proximal to hepatic flexure) 22 (67)
https://doi.org/10.1371/journal.pone.0208974.t001
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vs. 35 [10, 75], respectively). Laboratory values were not significantly different between UC and
CD patients at time of serum sampling (S1 Table). During follow-up, there was no difference in
medication use between UC and CD patients apart from the fact, that UC patients received signif-
icantly more often mesalazine. Complications included fistulas in 4 (14%) CD patients, strictures
in 2 (7%) CD patients, and extraintestinal manifestations in 7 (21%) UC and 10 (36%) CD
patients. 1 UC patients and 4 (14%) CD patients needed surgery during follow-up.
Single antibodies and their combinations for diagnosis of ulcerative colitis
and Crohn’s disease
The prevalence of antibodies in non-IBD patients was low with 2 (3%) being cANCA, 2 (3%)
MPO-ANCA, 2 (3%) ASCA, and 1 (1.5%) gGAB positive. None of the non-IBD controls were
positive for PR3-ANCA, pANCA, xANCA, or PAB, resulting in a relatively low sensitivity but
high specificity of these antibodies for IBD (S2 Table).
When testing for the differentiating capability of the single antibodies in IBD patients,
PR3-ANCA had the most balanced ratio of sensitivity and specificity for UC (58% and 93%,
respectively) (Table 2). PAB could be detected in UC as well as CD patients and was not able
to distinguish between both disease subtypes in our cohort (OR, 2.1; 95%CI; 0.7, 6.4; P = .208).
GAB and gGAB were positive only in a minority of UC and CD patients and it was not possi-
ble to differntiate between IBD subtypes.
To improve the diagnostic performance, we combined antibodies in a simple summation.
When combining PR3-ANCA positivity and xANCA positivity the specificity for UC
increased to 96%, however the sensitivity decreased to 36% with an OR of 15.4 (95%CI; 1.9,
128.3). For PR3-ANCA positivity in combination with ASCA negativity the sensitivity for UC
was 52% and the specificity 93% with an OR of 13.8 (95%CI; 2.8, 67.9).
Table 2. Antibody association with ulcerative colitis and Crohn’s disease.
Antibody CD UC p–value Odds Ratio (95%
confidence interval)
Sensitivity,
%
Specificity,
%
Positive predictive
value, %
Positive likelihood
ratio
ANCA
cANCA, n (%) 2 (7.4) 6 (18.2) 0.276 2.8 (0.5,15.1) 18 93 75 2.6
PR3-ANCA, n (%) 2 (7.1) 19 (57.6) <0.001 17.6 (3.6,87) 58 93 90 8.3
PR3-ANCA U/ml,
median [IQR]
1 [1, 1.65] 5.8
[1.6,13.8]
<0.001 - - - - -
pANCA, n (%) 0 (0) 2 (6.1) 0.497 - 6 100 100 -
MPO-ANCA, n (%) 1 (3.6) 3 (9.1) 0.618 2.7 (0.3,27.5) 9 96 75 2.3
MPO-ANCA U/ml,
median [IQR]
1 [1,1] 1 [1,1] 0.585 - - - - -
xANCA, n (%) 4 (14.8) 18 (54.5) 0.003 6.9 (1.9,24.4) 55 93 90 7.9
GAB, n (%) 3 (10.7) 1 (3.6) 0.611 3.2 (0.3,33.2) 4 89 25 0.3
ASCA
IgA, n (%) 13 (46.4) 3 (9.1) 0.001 8.7 (2.1,35.1) 46 91 81 5.1
IgA U/ml, median [IQR] 14.5
[7,72.5]
9 [5,13] 0.038 - - - - -
IgG, n (%) 15 (53.6) 5 (15.2) 0.001 6.5 (1.9,21.6) 54 85 75 3.6
IgG U/ml, median [IQR] 37 [6,70] 7 [4,17] 0.001 - - - - -
PAB, n (%) 10 (35.7) 7 (21.2) 0.208 2.1 (0.7,6.4) 36 79 59 1.7
gGAB, n (%) 7 (25) 3 (9.1) 0.164 3.3 (0.8,14.4) 25 91 70 2.8
https://doi.org/10.1371/journal.pone.0208974.t002
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Diagnostic panel as predictor for ulcerative colitis and Crohn’s disease
In a next step, the whole antibody profile was used as input for a quasi-exhaustive logistic
regression approach to calculate a best-fit antibody combination for prediction of the subtype
of IBD, UC and CD. The patients from one center (Bern, n = 44) served as a training cohort
(S3 Table). A panel including the positivity status of PR3-ANCA, xANCA, pANCA, and the
titer of ASCA IgG was returned. The coefficients for the computation of the predictor in the
logistic regression model were as follows: Intercept 0.5937, PR3-ANCA -0.4085, xANCA
-0.3280, pANCA -0.6299, and ASCA IgG 0.0052. The best cut-off value for the predictor was
Fig 1. ROC analysis best fit antibody panel: Training (blue line) vs validation (black line) cohort. shaded areas represent the 95%
confidence interval.
https://doi.org/10.1371/journal.pone.0208974.g001
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0.6245. The AUC in the training cohort reached 90.81% (95%CI; 81.93, 99.69). The predictive
accuracy of the antibody panel could be confirmed in the validation cohort (Lucerne, n = 17)
with an AUC of 84.29% (95%CI; 64.75, 100) (Fig 1).
Antibody profiles and disease behavior
Other than being used as a diagnostic tool, antibody profiling may also predict disease behav-
ior. ASCA IgA positive CD patients had a more complicated and severe disease course (stric-
turing or penetrating disease, need for surgery) (OR, 12.1; 95%CI; 1.2, 120.1; P = .029). ASCA
IgG positive CD patients were more likely to present with ileocolonic disease (L3) (OR, 6.2;
95%CI; 1.2, 32; P = .024). An increased number of positive antibody responses was associated
with a more complicated disease course (OR, 12.7; 95%CI; 1.6,120.3; P = .029) in CD patients.
No further associations for different antibodies or their combinations were identified for
neither UC nor CD patients. PR3-ANCA positivity was not associated with age at serum sam-
pling. There was no difference in disease extension nor the need for biologicals during follow-
up as a marker of disease severity between PR3-ANCA positive and negative UC patients (S4
Table). Of the 2 CD patients with PR3-ANCA positivity one patient had ileocolonic and proxi-
mal upper gastrointestinal (A1b, L3, L4a, B1) and the other colonic and proximal upper gastro-
intestinal (A1a, L2, L4a, B1) disease. There was no significant association (P = .2) between
upper disease location (L4a) and gGAB positivity, despite 5/13 (38%) CD patients fulfilling
both requirements.
Discussion
Establishing the diagnosis of IBD and assigning the correct subtype to individual patients can
still be challenging. In a pediatric and adolescent cohort of IBD patients, we could show that
PR3-ANCA is a strong marker for UC with preeminent sensitivity and specificity. Further-
more, a panel consisting of four antibodies, PR3-ANCA, xANCA, pANCA, and ASCA IgG,
showed a very good AUC of 90.8% to distinguish between CD and UC in a training cohort.
The validity of this panel was proven in a validation cohort (AUC = 84.1%).
Antibodies in ulcerative colitis
The presence of ANCA was found to have significant association with UC in our cohort. How-
ever, when interpreting and comparing ANCA data between studies varying definitions and
determination methods made direct comparison difficult [22]. In some IBD studies the expres-
sion “pANCA” has been synonymously used for atypical pANCA, in others there is no differ-
entiation between pANCA and atypical pANCA, and in some studies, the rim-like staining is
also referred to as being perinuclear [7,14,23–25]. To be more precise we used the term
xANCA only for the rim-like staining pattern as xANCA are the main ANCA found in UC
patients when performing IIF [26].
More importantly, none of the non-IBD controls was PR3-ANCA positive and PR3-ANCA
positivity had a reasonable sensitivity of 58% and specificity of 93% to distinguish UC from
CD patients based on their PR3-ANCA status in our cohort. The positive predictive value for
UC was good with 90%. Strikingly, PR3-ANCA were more prevalent in our pediatric and ado-
lescent group with UC (57.6%) than in the published adult groups (31% and 29%)[11,12]. One
factor may be that most of our patients already presented with a more extensive disease pheno-
type. This is consistent with the observation in adults showing a positive association between
PR3-ANCA and a more extensive disease location [12,27]. Interestingly, it was also shown in
adults that PR3-ANCA reactivity decreases with disease duration, being 48.5% with 0–2 years
and 16.7% with 17–20 years [12]. Whether this decrease is due to the effect of treatment can
PR3-ANCA and panel diagnostics in pediatric inflammatory bowel disease
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only be answered in longitudinal observations. However, this finding highlights the point that
antibody testing should be performed at initial diagnosis.
The combination of PR3-ANCA positivity with ASCA negativity did not improve the
sensitivity and specificity for UC in our cohort as it has been described in adults [11]. Yet,
combining PR3-ANCA reactivity with xANCA, the specificity for UC increased to 96%. How-
ever, the increase in specificity was associated with a simultaneous decrease in sensitivity. This
suggested that PR3-ANCA might be of value as a stand-alone marker in the differentiation of
UC from CD.
Antibodies in Crohn’s disease
ASCA is accepted as a highly specific marker for CD [28]. In our cohort ASCA positivity had a
reasonable sensitivity of 57% for any ASCA (ASCA IgA and/or ASCA IgG positive) and a spec-
ificity of 82%. These numbers are comparable to other published pediatric cohorts with sensi-
tivity of 42% and specificity of 89% for any ASCA [29]. As shown for adults the sensitivity and
specificity of ASCA can be optimized, when combining antibody results [30]. When combin-
ing ASCA positivity with PR3-ANCA negativity the specificity for CD in our cohort increased
to 88%, indicating that a combination with PR3-ANCA reactivity has a higher diagnostic value
than focusing on single antibodies.
Panel diagnostics
The advantage of using a panel over simple summation of single markers is the possibility to
weigh each marker and to enhance the granularity. However, most published panels in IBD
diagnostic include antibodies that are not available in routine laboratories [7,31–33] or even
include genetic in combination with inflammatory markers [31,34]. Additionally, most studies
only report on a training cohort and have not included a validation cohort in their analysis.
One pediatric study used ASCA IgA, ASCA IgG, ANCA, and an antibody to the outer
membrane protein of E. coli (OmpC) in a four- antibody panel and achieved a sensitivity of
65% for CD and 76% for UC, with a specificity of 94% [32]. In an adult cohort an antibody
panel consisting of ASCA IgA, ASCA IgG, OmpC, anti-flagellin (Cbir1), ANCA, and pANCA
discriminated patients with CD and UC with an AUC of 0.78 (95%CI; ± 0.06) [34]. Our panel
consisting of ASCA IgG, xANCA, pANCA and PR3-ANCA shows superiority using only four
markers, having an AUC in the training cohort of 0.90 (95%CI; 0.81, 0.99) and an AUC of 0.84
(95%CI; 0.64, 1.00) in the external validation cohort. The discrepancy of only 6% of the AUC
between the training and validation cohort supports a good validation. The limited number of
antibodies also reduced the risk of model over-fitting. Additionally, including only clinically
routinely available markers in a panel allows its broad usage. This panel may become a predic-
tor in patients with IBD- unclassified (IBD-U), where the final diagnosis will only be made
over time. A longitudinal multicenter study employing our panel is needed to prove this
possibility.
Antibodies for prediction of disease location and behavior
We confirmed in a pediatric population the findings of Elkadri et al. [7] that ASCA positivity
in CD patients is associated with ileocolonic disease and can predict a more complicated and
severe disease course. Additionally, we also found that an increased number of positive anti-
body responses is associated with a more complicated disease pattern in CD patients [7].
Recently the interest in PAB as a marker for CD has increased [35]. However, in compari-
son to adult studies PAB reactivity was not able to distinguish between CD and UC in our
cohort [13,24]. The high prevalence of PAB reactivity in our UC patients, which was also
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found in another pediatric study, may explain this finding [14]. In concordance with the find-
ings of Kovacs [14], we could not demonstrate an association between PAB positivity and
extra-intestinal manifestations, complicated disease course or need for therapy with biologics
in pediatric patients as suggested in adults [36].
Although GAB is thought to be associated with UC, we found it more often in CD patients.
However, in total only 7% IBD patients in our cohort were positive, which is a much lower prev-
alence than previously described in adults being around 30% [37]. In an IIF study using human
tissue from different intestinal locations a trend was seen with CD sera preferentially staining
goblet cells in the small intestine and UC sera staining goblet cells in the sigmoid and rectum
[16]. This may suggest a possible relation between reactivity pattern and disease location. In our
study however, there was no association between upper GI tract disease and gGAB reactivity
when using murine gastric tissue. Further studies including more patients with upper GI tract
disease location are needed to draw a conclusion of the value of gGAB determination.
Strengths and limitations
We acknowledge the small sample size as the main limitation of our study. However, including
patients with a short time lapse from diagnosis and serum sampling allows concluding that
PR3-ANCA determination can be of value in early differentiation of UC from CD patients
based on their serological antibody profile. Another strength is the employment of patients
from two different centers. This allowed us to use the proposed antibody panel in a training
and in a validation cohort, which improved the validity of the panel. Additionally, the use of
routinely available markers makes the information accessible and useful for the clinician.
Conclusion
PR3-ANCA and the combination of antibodies in a panel consisting of PR3-ANCA, pANCA,
xANCA, and ASCA IgG improves diagnostic accuracy in differentiating between CD and UC.
The prognostic value of antibody determination however seems to be limited as prediction of
disease behavior was indefinite when compared to published associations.
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